Project Grant R01CA315660
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $538K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded the University of Texas MD Anderson Cancer Center $645,865 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate how perineural invasion in cutaneous squamous cell carcinoma drives immunotherapy resistance through neuroimmune mechanisms. The research addresses the molecular pathway linking nerve invasion to tumor immune suppression. The project will investigate how activating transcription factor 3 (ATF3)-dependent transcriptional...
- The National Institutes of Health National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $680,129 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth. The award funds development of three integrated components: a rat tumor model with cirrhosis background to serve as a clinically translatable animal model; resorbable polymeric scaffolds with...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,739 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to unravel the molecular mechanisms of immunotherapy-associated myocarditis. The research investigates how immune checkpoint inhibitors, which enhance anti-tumor immune responses in cancer treatment, trigger myocarditis—inflammation of the heart that carries mortality rates up to 50 percent. The project uses mouse models...
- The Defense Health Agency awarded The University of Texas MD Anderson Cancer Center $1,399,964 on September 16, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support accelerating translational therapeutics from target discovery to clinical application for pancreatic cancer and beyond. Work is performed in Houston, Texas, with a period of performance through September 14, 2029. The award funds a project grant supporting MD Anderson's translational oncology...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $645,186 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop lung cell transplantation therapies for chemotherapy-induced pulmonary fibrosis in cancer patients. The research addresses a significant clinical gap: chemotherapy drugs including bleomycin, methotrexate, and oxaliplatin induce pulmonary fibrosis in cancer patients, and lung transplantation—the only currently...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $995,981 on September 9, 2025, under the Cancer Biology Research program (CFDA 93.396) to decipher the role of cancer pain-associated neuronal activity in driving malignancies, with work continuing through August 31, 2030. The research addresses the hypothesis that a feedforward mechanism exists between cancer pain-associated sensory neuron hyperactivity and malignant peripheral nerve sheath tumor (MPNST)...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $150,404 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training and fellowship activities for individuals pursuing careers in cancer research. The award funds investigation of gut microbiome dysbiosis in lung adenocarcinoma development and progression. The research dissects how gut microbial changes, particularly those involving loss of LCN2 (an...